Author:
Keam Susan J.,Duggan Sean
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Seebacher NA, Stacy AE, Porter GM, et al. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38:156.
2. National Medical Products Administration. Donafenib: NMPA approval notice [media release]. 9 Jun 2021. https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20210609085421166.html.
3. Zelgen. Donafenib tosylate tablets: Chinese prescribing information. Kunshan City: Suzhou Zejing Biopharmaceutical Co Ltd; 2021.
4. Zelgen. R&D: clinical research. 2021. https://www.zelgen.com/en/index.php/chanpinxian/. Accessed 4 Aug 2021.
5. Zhong L, Hou C, Zhang L, et al. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers. 2019;23(2):341–50.
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献